Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 7/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15980920 | 0.89 | PTPN1 (0.36) | IMPDH2CYP19A1LMNATSHRHSD17B10 | |
| SCHEMBL806720 | 0.85 | HTR2A (0.34) | IMPDH2MAPTHTR2ATAAR1CYP19A1 | |
| SCHEMBL806744 | 0.84 | KDM4E (0.38) | IMPDH2MAPTCYP19A1HSD17B10 | |
| SCHEMBL806715 | 0.84 | PTPN1 (0.39) | IMPDH2MAPT | |
| SCHEMBL15980405 | 0.83 | BACE1 (0.41) | MAPTLMNA | |
| SCHEMBL806897 | 0.78 | CYP3A4 (0.38) | MAPTHTR2ATAAR1HTR2C | |
| SCHEMBL15980584 | 0.77 | HTR2A (0.40) | MAPTHTR2ATAAR1LMNAHTR2C | |
| SCHEMBL15980355 | 0.74 | HTR2A (0.39) | MAPTHTR2ATAAR1LMNAHTR2C | |
| SCHEMBL15978364 | 0.74 | APP (0.44) | IMPDH2MAPTLMNA | |
| SCHEMBL8512148 | 0.71 | LMNA (0.40) | MAPTCYP19A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243404-A1 | UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012037069-A2 | UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243404-A1 | UNIQUE HALOGEN-INDUCED CYCLIZATIONS, REAGENTS THEREFOR, AND COMPOUNDS PRODUCED THEREBY | WEE1, WEE2, NOTUM | IMPDH2 2395/4885MAPT 4714/4885HTR2A 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.